Abstract
Options for patients with non–small cell lung cancer have expanded following trials studying the safety and efficacy of checkpoint inhibitors and targeted therapies. Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, of MD Anderson Cancer Center reviews the major abstracts from the 2019 ASCO Annual Meeting using coverage by The ASCO Post and offers considerations for advanced practitioners in this field.
